Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis by Liu, Jiannong et al.
© 2009 Liu et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management
Therapeutics and Clinical Risk Management 2009:5 319–330 
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
O R i g i n A L   R e s e A R C h
Associations of anemia persistency with medical 
expenditures in Medicare esRD patients on dialysis
Jiannong Liu1 
haifeng guo1 
David gilbertson1 
Robert Foley1,2 
Allan Collins1,2
1Chronic Disease Research group, 
Minneapolis Medical Research 
Foundation, Minneapolis, Mn, UsA; 
2Department of Medicine, University 
of Minnesota, Minneapolis, Mn, UsA
Correspondence:  Jiannong Liu 
Chronic Disease Research group,  
Minneapolis Medical Research Foundation,   
914 south 8th street, suite s-253,  
Minneapolis, Mn 55404, UsA 
Tel +1 612 347 7695 
Fax +1 612 347 5878 
email jliu@cdrg.org
Abstract: Most end-stage renal disease (ESRD) patients begin renal replacement therapy with 
hemoglobin levels below the recommended US National Kidney Foundation Dialysis Outcomes 
Quality Initiative Guidelines lower level of 110 g/L. Although most patients eventually reach 
this target, the time required varies substantially. This study aimed to determine whether length 
of time with below-target hemoglobin levels after dialysis initiation is associated with medical 
costs, and if so, whether intermediate factors underlie the associations. US patients initiating 
dialysis in 2002 were studied using the Centers for Medicare and Medicaid Services ESRD 
database. Anemia persistence (time in months with hemoglobin below 110 g/L) was deter-
mined in a six-month entry period, and outcomes were assessed in the subsequent six-month 
follow-up period. The structural equation modeling technique was used to evaluate associations 
between persistent anemia and medical costs and to determine intermediate factors for these 
associations. The study included 28,985 patients. Mean per-patient-per-month medical cost was 
$6267 (standard deviation $5713) in the six-month follow-up period. Each additional month 
with hemoglobin below 110 g/L was associated with an 8.9% increment in medical cost. The 
increased cost was associated with increased erythropoietin use and blood transfusions, and 
increased rates of hospitalization and vascular access procedures in the follow-up period.
Keywords: anemia persistency, end-stage renal disease, medical costs, structural equation 
modeling
Introduction
For dialysis patients in the United States, hemoglobin levels have increased yearly since 
erythropoietin-stimulating agents (ESA) were introduced into clinical practice in 1989.1 
In early 1991, the mean hemoglobin level for end-stage renal disease (ESRD) patients 
was 96 g/L, and the level for 84.5% of patients was below the recommended National 
Kidney Foundation Dialysis Outcomes Quality Initiative (KDOQI) Guidelines lower 
target level of 110 g/L.2,3 By June 2005, the mean hemoglobin level had increased 
to 119 g/L and levels were below 110 g/L for only 19.4% of patients.1 In contrast to 
the temporal trends in the overall population, most incident patients begin dialysis 
treatment with hemoglobin levels below 110 g/L. In 2005, values were below 110 g/L 
for 67.4% of incident patients at dialysis initiation,1 and the time required to reach 
the target level varies considerably. Low hemoglobin in ESRD patients is associated 
with increased mortality, morbidity, hospitalization, and medical costs; these asso-
ciations are well documented.4–11 One study also shows that longer time required to 
reach the target hemoglobin level was associated with significantly higher risk of 
hospitalization and mortality.12 The present study was designed to address whether Therapeutics and Clinical Risk Management 2009:5 
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persistent anemia, measured by length of time after dialysis 
initiation with hemoglobin levels below 110 g/L, is associated 
with economic outcomes, and if so, whether intermediate 
factors, through which persistent anemia affects outcomes, 
underlie these associations?
Methods
study population
This study includes 2002 incident US ESRD patients with 
hemodialysis as renal replacement therapy and Medicare as 
primary payer at day 91 after dialysis initiation. A six-month 
entry (baseline) period was defined from dialysis months 
4–9. Months 1–3 were not used because data are incomplete 
for many patients. Patients who died, underwent transplant, 
changed primary payer, or whose hemoglobin was unreported 
or outside the range 33–183 g/L in one or more months of 
the six-month entry period were excluded. Patients were 
followed from the first day after the entry period to the first 
of death, undergoing transplant, changing primary payer, or 
six months.
Data sources and patient baselines
Data used for this study came from the Centers for Medicare 
and Medicaid Services (CMS) Renal Management Infor-
mation System (REMIS) and CMS Standard Analytical 
Files. The REMIS database includes information from the 
CMS Medicare Enrollment Database, the United Network 
for Organ Sharing transplant database, the ESRD Medical 
Evidence Report (form CMS-2728), and the ESRD Death 
Notification (form CMS-2746). The Standard Analytical 
Files include Medicare Part A institutional claims (inpatient, 
outpatient, skilled nursing, home health, and hospice) and 
Part B physician/supplier claims.
Patient baseline information included demographic 
characteristics, hospital days and hemoglobin levels in the 
entry period, and comorbid conditions. Demographic charac-
teristics, including age, sex, race (white, African American, 
other), and ethnicity (Hispanic, non-Hispanic), were obtained 
from the REMIS database. Duration of hospital stays in the 
entry period was obtained from Part A inpatient claims in 
the Standard Analytical Files.
Comorbid conditions were characterized from Medicare 
Part A and Part B claims in the entry period, using 
International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) and Physicians’ Current 
Procedural Terminology (CPT) codes (see Appendix for 
the specific codes). Conditions characterized were diabetes, 
atherosclerotic heart disease (ASHD), congestive heart failure 
(CHF), peripheral vascular disease (PVD), cerebrovascular 
accident/transient ischemic attack (CVA/TIA), dysrhythmia, 
other cardiac diseases (including pericarditis, endocarditis, 
myocarditis, other complications of heart disease, heart 
transplant, heart valve replacement, and cardiac devices), 
cancer, liver disease, gastrointestinal bleeding, and chronic 
obstructive pulmonary disease (COPD). The method used 
for defining comorbid conditions from claims has been 
previously described.13
Patient hemoglobin values were obtained from the 
Medicare recombinant human erythropoietin (EPO) claims 
files derived from the outpatient Standard Analytical Files. 
For each patient, mean hemoglobin value was computed 
for each entry period month and for the entire entry period. 
The mean number of months with hemoglobin values below 
110 g/L in the entry period was calculated for the overall 
cohort. Anemia persistence was described by number of 
months with hemoglobin values below 110 g/L in the entry 
period. To demonstrate the robustness of the analysis, we 
characterized persistent anemia in 2 additional ways: whether 
the number of months with hemoglobin level below 110 g/L 
was higher than the overall cohort mean number of months, 
and mean hemoglobin level in the entry period.
Outcomes
In the follow-up period, total EPO dose, total number of  blood 
transfusions, hospital days, and number of vascular access 
procedures were derived from Medicare Part A and Part B 
claims. Per-patient-per-month (PPPM) Medicare allowable 
costs were obtained from Medicare Part A and Part B claims. 
Institutional Medicare allowable costs include Medicare 
payment, coinsurance, deductibles, and any payment provided 
by a payer other than Medicare. Costs in the follow-up period 
were summed for each patient and divided by the number of 
follow-up months to obtain PPPM cost.10
statistical analysis
Patient baseline characteristics were tabulated overall and by 
persistent anemia groups. Differences among groups were 
assessed using the chi-square test for categorical variables 
and the Wilcoxon rank sum test for continuous variables. 
Means and medians of EPO dose, number of blood transfu-
sions, number of hospitalization days, and number of vascular 
access procedures in the follow-up period were also tabulated 
by persistent anemia group, and differences among groups 
were tested using the Wilcoxon rank sum test.
The structural equation modeling (SEM) technique was 
used to evaluate the associations between persistent anemia Therapeutics and Clinical Risk Management 2009:5 
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and medical costs and to assess the intermediate clinical 
factors underlying these associations. SEM is a combination 
of path analysis and factor analysis14,15 that has been widely 
used in the psychological, behavioral, and social sciences 
and was introduced to medical research recently.16–18 Because 
SEM allows several regression equations to be tested simulta-
neously, it characterizes both the overall association between 
independent and dependent variables and intermediate factors 
that describe the nature of the association.
Because SEM is most effective when data, especially 
endogenous (dependent) variables and latent variables (factors 
measured by one or more variables) indicators, are normally 
distributed, the continuous variables in our data were checked 
for normality and transformed if necessary. Instead of the 
original values for PPPM, EPO dose, and numbers of transfu-
sions, hospitalization days, and vascular access procedures, the 
natural logarithm of PPPM expenditures and the square roots of 
EPO dose and numbers of blood transfusions, hospitalization 
days, and vascular access procedures were used in the models. 
Because outlier PPPM costs can cause severe skewness, 
patients whose costs were above the highest 0.25th percentile 
or below the lowest 0.25th percentile were excluded.
To reduce the number of variables in the analysis and the 
number of categorical variables in the model, a comorbidity 
score was used in the models to replace the binary comor-
bidity variables. To obtain the comorbidity score, a linear 
regression model was fit with logged PPPM as dependent 
variable and age, sex, race, ethnicity, number of months 
with hemoglobin values below 110 g/L, duration of hospi-
talizations in the entry period, and all individual comorbid 
conditions as independent variables. A weight was assigned 
to each comorbid condition associated with logged PPPM 
(p  0.05 in the regression model). Weights were multiplied 
up relative to the smallest parameter estimate and in whole-
number increments. For example, the smallest parameter 
estimate for the significant comorbid conditions is 0.01642 
for COPD, the parameter estimate for CHF is 0.0325, and 
the parameter estimate for CVA is 0.04935; we assigned 
weight 1 to COPD, weight 2 to CHF, and weight 3 to CVA. 
We assigned weight 1 to ASHD, COPD, and liver disease, 2 
to CHF and other cardiovascular disease, 3 to CVA and PVD, 
and 4 to cancer. Gastrointestinal bleeding and dysrhythmia 
were nonsignificant. The comorbidity score for each patient 
was the sum of the weights based on the presence or absence 
of the comorbid conditions. In SEM, all relationships between 
endogenous variables and the corresponding exogenous 
variables should be linear. Plots and regression residual plots 
showed that the assumptions of linearity were met.
We hypothesized that the relationship between persistent 
anemia and total (all cause) medical cost was mediated by 
two factors: (1) anemia treatment and (2) general severity of 
illness. The anemia treatment factor was measured as EPO 
dose and number of blood transfusions in the follow-up 
period. The general severity of illness factor was measured 
by number of inpatient hospital days and number of vascular 
access procedures in the follow-up period. Mathematically, 
our assumed model is
	 Y	=	X1β1	+	X2β2	+	ε	 (1)
	 X1	=	X2γ	+	ε1	 (2)
where Y is log(PPPM); X1 includes anemia treatment (the 
common factor of EPO dose and number of transfusions in the 
follow-up period) and general severity of illness (the common 
factor of hospitalization days and number of vascular access 
procedures in the follow-up period); X2 includes age, race, 
sex, ethnicity, number of hospital days in the entry period, 
comorbidity score and persistent anemia; ε and ε1 are 
residuals. A graphic expression of models (1) and (2) is 
displayed in Figure 1. For simplicity and clarity, all baseline 
variables except persistent anemia are grouped together, in 
a box labeled “Baseline variables.” An arrow from one box 
to another, such as “Baseline variables” to “Medical costs,” 
means that the baseline variables were hypothesized to affect 
medical costs in the follow-up period. To assess whether 
persistent anemia was associated with medical costs in ways 
other than those intermediated by anemia treatment and gen-
eral severity of illness, persistent anemia was included in X2 in 
regression model (1), representing the total of the direct and 
other indirect associations, if any, between persistent anemia 
and medical costs, other than associations intermediated by 
anemia treatment and general severity of illness.
Results
The study cohort comprised 28,985 incident patients. Figure 2 
illustrates in detail the study exclusion criteria by which patients 
were selected. Mean number of months with hemoglobin values 
below the target value of 110 g/L was 1.3 (Table 1). Persistent 
anemia groups were defined in three ways: number of months 
with hemoglobin values below 110 g/L (0, 1 to 2, or 3); whether 
the number of months with hemoglobin value below 110 g/L 
was  or 1.3, the cohort mean; and whether mean hemoglobin 
over the entry period was  or 110 g/L. Younger age, female 
sex, African American race, Hispanic ethnicity, hospitalization 
during the entry period, and each comorbid condition studied were 
associated with persistent anemia. In the six-month follow-up 
period, mean follow-up time was 5.63 months per patient, and Therapeutics and Clinical Risk Management 2009:5 
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Figure  graphical expression of assumed model.  For simplicity and clarity,  all baseline variables except persistent anemia appear together in a box labeled “Baseline variables.” 
An arrow from one box to another, such as “Baseline variables” to “Medical costs,” means that the baseline variables were hypothesized to affect medical costs in the follow-up 
period. The e1–e7 are residuals.
average medical cost was $6267 per patient per month in the 
follow-up period.
Among persistent anemia groups, compared with 
the zero-month group, the one-to-two months group 
and  three-months group had mean values that were 47.6% 
and 155.1% higher for EPO doses, 41.2% and 252.9% higher 
for number of blood transfusions, 26.9% and 98.4% higher 
for number of hospital days, and 16.2% and 39.1% higher for 
number of vascular access procedures, respectively, in the 
follow-up period (Table 2). The corresponding cost showed 
the same relationship with persistent anemia. Results were 
similar for the other anemia persistency measures.
Compared with PPPM cost for patients with zero months 
with hemoglobin level below 110 g/L, mean PPPM costs 
for patients with one to two months and  three months 
below 110 g/L were 14.9% and 47.8% higher, respectively 
(Table 3). The incremental costs were 29.3% higher for 
the 1.3-months group than for the 1.3-months group, 
and 43.7% higher for the group with mean hemoglobin 
below 110 g/L than for the group with mean hemoglobin 
above 110 g/L.
The β1 in the structural equation model in Figure 1 was 
tested nonsignificant (the estimate is −0.006 and the  p-value 
is 0.622). Thus, except for associations intermediated by Therapeutics and Clinical Risk Management 2009:5 
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Did not have Medicare parts 
A and B at start of entry 
period, n = 41,255 (41.9%)
During entry period, died, 
underwent transplant, or
changed primary payer, 
n = 9585 (9.7%)
Hemoglobin values outside 
the range 33–183 g/L or 
unreported in 1 or more months 
of the entry period,
n = 18,412 (18.7%)
No allowable costs in the 
entry period, n = 16 (0.02%)
Allowable costs in follow  up
period in upper or lower 
0.25%, n = 146 (0.15%)
Began maintenance dialysis in 
2002, n = 98,399
After coverage exclusions,
n = 57,144 (58.1%)
After exclusions due to changes during 
entry period, n = 47,559 (48.3%) 
After hemoglobin value 
exclusions, n = 29,147 (29.6%)
After allowable costs exclusion, 
n = 29,131 (29.6%)
After outlier costs exclusion, 
n = 28,985 (29.5%),
final sample
Figure  Flow chart for patient selection from the Centers for Medicare and Medicaid services end-stage renal disease database.
anemia treatment and general severity of illness in the follow-up 
period, there is no other association between persistent anemia 
and medical costs, or it is too small to detect. Except β1, all asso-
ciations on paths from persistent anemia to medical cost are sig-
nificant (all  p-values are  0.0001). The model was rerun with 
β1 = 0. The model fits the data very well. The R-square for logged 
PPPM is 0.812; Goodness of Fit Index = 0.976, Normed Fit 
Index = 0.91, Root Mean Square Error Approximation = 0.057. 
Table 4 summarizes findings from structural equation models 
assessing associations between medical costs and persistent 
anemia. Persistent anemia was associated with future medical 
costs, an association that persisted when adjustment was made 
for age, sex, race, ethnicity, diabetes, comorbid conditions, 
and baseline length of hospital stay. Each additional month 
with hemoglobin below 110 g/L was associated with an 8.9% 
cost increment (because the log scale was used for costs, 
the total percent change has a multiplicative, not an additive 
relationship, here 1.036 × 1.051 ≈ 1.089 [95% confidence Therapeutics and Clinical Risk Management 2009:5 
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Table  Association between persistent anemia and medical costs from structural equation models
Association Months with hemoglobin 0 g/L
Continuous variablea .b Mean hemoglobin
γ11 (se) 0.044 (0.001) 0.09 (0.003) −0.64 (0.002)
γ12 (se) 0.321 (0.016) 0.79 (0.043) −0.474 (0.023)
β3 (se) 0.789 (0.048) 0.822 (0.065) 0.789 (0.049)
β4 (se) 0.158 (0.004) 0.157 (0.004) 0.158 (0.004)
effect through anemia treatment
  effect at log scale 0.035 0.074 −0.05
    Percentage change at the original scale 3.6 7.7 −4.9
effect through general severity of illness
  effect at log scale 0.05 0.124 −0.075
    Percentage change at the original scale 5.1 13.2 −7.2
Total effect (se)c
  effect at log scale 0.085 (0.003) 0.198 (0.008) −0.125 (0.004)
    Percentage change at the original scale 8.9 (0.027) 22.0 (0.176) −11.8 (0.047)
Notes: anumber of months with hemoglobin value below 110 g/L. bThe cohort mean number of months with hemoglobin values below 110 g/L is 1.3. cBootstrap standard error.
Abbreviation: se, standard error.
association between persistent anemia and future medical 
costs was mainly explained by associations with future EPO 
doses, blood transfusions, hospitalizations, and vascular 
access procedures in the follow-up period. Hospitalization 
and vascular access (the indirect costs) appeared to be the 
more important component of the anemia/cost relationship.
Our finding that persistent anemia is associated with higher 
medical costs is consistent with previous studies,9–11 but our 
methodology may represent a level of robustness not seen in 
other observational studies. Structural equation modeling is 
attractive because it can incorporate complex relationships 
among the endogenous and exogenous variables. It not 
only models the association between persistent anemia and 
medical costs, but also assesses the intermediate factors for 
interval 8.2%–9.4%]). Similarly, each one-unit increase in 
mean hemoglobin in the entry period was associated with an 
11.8% decrease in medical costs (95% confidence interval 
10.1%–12.4%). Medical costs for the 1.3-months group 
were 22.0% higher than for the  1.3-months group. The 
adjusted difference between the  and 1.3-months groups 
was smaller than the unadjusted difference (22.0% vs 29.3%) 
because the 1.3-months group was more ill, with more 
comorbid conditions and more hospital days in the entry 
period (see Table 1).
Discussion
This study shows that persistent anemia after dialysis therapy 
initiation is followed by increased medical costs and that the 
Table  Mean, median, 25th and 75th percentiles of per patient per month costs in dollars in the follow-up period by persistent anemia 
group
Baseline months with hemoglobin 0 g/L Baseline mean hemoglobin
Per patient per 
month costs, $
0  to   Pa .b .b Pa 0 g/L 0 g/L Pa
n 11,450 12,154 5381 18,580 10,405 25,315 3670
0.001 0.001 0.001
Meanc (sD) 5461 (494) 6276 (554) 8070 (691) 5684 (511) 7349 (643) 5958 (530) 8562 (737)
Median 4180 4919 6802 4376 5985 4616 7390
25th–75th percentiles 3092–6671 3481–8051 4399–10,998   3188–7037 3954–9954   3293–7498 4763–11,946  
Notes: aP values obtained by Wilcoxon rank-sum test. bThe cohort mean number of months with hemoglobin values below 110 g/L is 1.3. cWeighted mean with follow-up 
time as weight.
Abbreviation: sD, standard deviation.Therapeutics and Clinical Risk Management 2009:5 0
Liu et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
the association. A 6-month follow-up period, much shorter 
than most other studies, was used because hemoglobin levels 
change frequently over even short time periods,19 and these 
changes during the follow-up period could affect outcomes 
if the follow-up time were longer. Assessing the effect of 
persistent anemia on medical cost would thus be impossible. 
Our shorter follow-up period avoids this problem.
For incident ESRD patients starting dialysis, minimizing 
time with hemoglobin values below 110 g/L may need to be 
balanced against the potential for exceeding target hemo-
globin levels, which appears to be common.1 Although the 
higher hemoglobin levels, like the levels below 110 g/L, 
may be transient, safety concerns related to higher targeted 
hemoglobin levels were reported in the Normal Hematocrit 
Study20 and the Correction of Hemoglobin and Outcomes 
in Renal Insufficiency (CHOIR) study.21 Adverse morbidity 
and mortality outcomes occurred in the higher hemoglobin 
target group, a finding that should be carefully considered. 
Conversely, the lower hemoglobin levels are also of concern 
because they also appear to be linked to morbidity and costs. 
Time within the target hemoglobin range of 110 to 120 g/L 
may be the best measure of successful anemia treatment.
Because more than 90% of patients had at most three 
months with hemoglobin values below 110 g/dL, the effect of 
patients with more than three months on the parameter estimate 
was weak. Therefore, interpretation of results should focus 
on patients with hemoglobin values below 110 g/L for three 
months or less. Similarly, interpretation of the results should 
focus on patients with mean hemoglobin values between 
100 and 130 g/L, because mean hemoglobin values for most 
patients fell in this range. It should be noted that achieved 
patient hemoglobin levels are the result of the target hemo-
globin level, treatment, and patient health status. The target 
range was likely 110–130 g/L for most of patients, because that 
was the KDOQI recommended target range during the study 
period. The results of this study are consistent with results in 
the Normal Hematocrit Study20 in the sense that for each target 
group, those with higher hematocrit had better outcomes.
The limitations of this study are related to its retrospective 
design and its reliance on administrative claims. Though the 
results are adjusted for numerous baseline patient factors, 
residual confounding remains possible and likely. Also, 
the results are adjusted for patient comorbid conditions, 
but condition severity, which might be associated with 
both persistent anemia and medical costs, is not available 
in the data. Survival for nine months (three months before 
the entry period and six months during the entry period), 
primary coverage by Medicare Parts A and B, and six 
months of hemoglobin reports in the entry period were study 
entry criteria, and the findings may not be generalizable to 
all incident patients numerically; however, the pattern of 
associations should be the same.
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International Classification of Diseases, Ninth Revision, Clinical Modification (iCD-9-CM) Codes, Current Procedural Terminology (CPT) Codes, and V-Codes 
Used to Define Comorbid Conditions and Vascular Access
Condition/Access ICD-9-CM Code/CPT Code V-code
Atherosclerotic heart disease 410.xx–414.xx V45.81;  V45.82
Congestive heart failure 398.91; 422.xx; 425.xx; 428.xx; 402.x1; 404.x1; 404.x3 V42.1
Cerebrovascular accident/transient ischemic attack 430.xx–438.xx
Peripheral vascular disease 440.xx–444.xx; 447.xx; 451.xx–453.xx; 557.xx
Cardiac (other) 420.xx–421.xx; 423.xx–424.xx; 429.xx; 785.0–785.3 V42.2;  V43.3
Chronic obstructive pulmonary disease 491–494; 496.xx; 510.xx
gastrointestinal bleeding 456.0–456.2; 530.7; 531–534; 569.84; 569.85; 578
Liver disease 570.xx; 571.xx; 572.1; 572.4; 573.1–573.3 V42.7
Dysrhythmia 426.xx–427.xx V45.0x;   V53.3x
Cancer 140.xx–172.xx; 174.xx–208.xx; 230.xx–231.xx; 233.xx–234.xx
Diabetes 250.xx; 357.2; 362.0x; 366.41
Vascular access CPT code 36800 alone; CPT codes 36488, 36489, 36490,  
36491, 36533 associated with diagnosis codes 250.xx, 403.xx,  
593.xx, V56.x, 996.1, 996.62, 996.73, V45.1, or 580.xx–589.xx
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